SOUTH SAN FRANCISCO, Calif., Aug. 14, 2023 — Spiral Therapeutics, Inc. (“Spiral”), a clinical-stage company delivering therapies for inner ear disorders, is proud to announce the participation of its Chief Executive Officer, Hugo Peris, at the forthcoming 3rd Inner Ear Disorders Therapeutics Summit. The event is scheduled to take place from August 29-31, 2023, in Boston, MA.
Mr. Peris will participate in two panels at the summit, contributing to discussions on “Improving Drug Delivery for Inner Ear Treatments” and on “Investing in the Inner Ear Disorder Field”. These sessions highlight Spiral Therapeutics’ ongoing commitment to the industry’s progress.
Dates for Panels:
“Improving Drug Delivery to Unlock the Opportunity for Inner Ear Therapeutics”
Date: Wednesday, August 30, 2023
“Key Considerations when Investing in the Inner Ear Disorder Space”
Date: Thursday, August 31, 2023
About Spiral Therapeutics
Spiral Therapeutics is a clinical-stage company focused on delivering therapies for inner ear disorders. Spiral’s novel drug delivery platform allows for minimally invasive, precise and durable exposure of drugs to the cochlea. Spiral is advancing a therapeutic pipeline with focus on hearing loss and balance disorders. Spiral’s lead program, SPT-2101, is a proprietary sustained-release steroid formulation for the treatment of inner ear inflammation. For more information, visit: www.spiraltx.com